CLYM

#2614
Climb Bio, Inc. - Common Stock
13.8 8 USD
-0.05%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
13.76
14.03
Jahresspanne
5.31
18.33
Tagesänderung
-4.74%
Monatliche Änderung
+16.74%
6 month change
+102.92%
Jahresänderung
+153.75%
Vorheriger Schlusskurs
14.5 7
Open
13.9 3
Tief
13.7 6
Hoch
14.0 3
Volumen
361
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Climb Bio, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Climb Bio, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Climb Bio, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Climb Bio, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Climb Bio, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Climb Bio, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Climb Bio, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Climb Bio, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Climb Bio, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Climb Bio, Inc. current report, Q2 FY2026
8-K

Climb Bio, Inc. current report, Q2 FY2024

Full document

Business Context and Reporting Period

This Form 8-K reports on the results of the 2024 Annual Meeting of Stockholders held by Eliem Therapeutics, Inc. (trading symbol: ELYM) on June 26, 2024. The filing details the approval of a merger with Tenet Medicines, Inc. and the election of new directors.

Key Financial Metrics

This filing is a current report regarding corporate governance and transaction approvals. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.

Material Changes and Transaction Details

  • Merger Approval: Stockholders approved the "Share Issuance Proposal" required to consummate the acquisition of Tenet Medicines, Inc. This approval satisfied conditions under Nasdaq Listing Rule 5635 and the Acquisition Agreement dated April 10, 2024.
  • Voting Results:
    • Baseline Vote: 26,311,239 votes For; 3,253 votes Against; 979 Abstentions.
    • Disinterested Stockholder Approval: 12,655,083 votes For; 3,253 votes Against; 979 Abstentions.
  • Board Elections: Andrew Levin, M.D., Ph.D., and Liam Ratcliffe, M.D., Ph.D., were elected to the Board of Directors to serve until the 2027 annual meeting.
  • Auditor Ratification: Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.

Guidance, Outlook, and Risks

Outlook: Based on the meeting results, the acquisition and concurrent private placement (PIPE) are expected to be consummated on or about June 27, 2024, subject to the satisfaction of remaining closing conditions.

Risks and Contingencies: The filing includes forward-looking statements subject to risks including:

  • Failure to complete the acquisition or financing in a timely manner or on anticipated terms.
  • Uncertainty regarding the satisfaction or waiver of closing conditions.
  • Potential delays impacting the combined company's cash and cash equivalents.
  • Unexpected costs, charges, or expenses related to the transaction.
  • Legal proceedings or changes in applicable laws and regulations.

Investor Verification Checklist

  • Verify the final closing date of the merger with Tenet Medicines, Inc., currently expected around June 27, 2024.
  • Review the definitive proxy statement filed on June 4, 2024, for detailed terms of the Acquisition Agreement and Securities Purchase Agreement.
  • Monitor for any announcements regarding the satisfaction of remaining closing conditions.
  • Confirm the post-transaction capital structure and share count following the issuance of shares to Tenet and PIPE investors.